NCT04569838 - A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

Indolent B-Cell Non-Hodgkin's Lymphomas

Interventions

DRUG

Bendamustine hydrochloride injection

Bendamustine is a bifunctional alkylating agent. It cross-links DNA single strand and double strand by alkylation,then destroys the function and synthesis of DNA, and makes the DNA and protein, protein and protein cross-linking, has potential to treat various tumors

Trial Locations (11)

215006

Affiliated Hospital of Nantong University, Nantong

The Second Affiliated Hospital of Soochow University, Suzhou

350014

Fujian Cancer Hospital, Fuzhou

430079

Hubei Cancer Hospital, Wuhan

450008

Henan Cancer Hospital, Zhengzhou

510060

Sun Yat-sen University Cancer Center, Guangzhou

510180

Guangzhou First People's Hospital, Guangzhou

510515

Southern Medical University Nanfang Hospital, Guangzhou

518020

Shenzhen People's Hospital, Shenzhen

528000

First People's Hospital of Foshan, Foshan

530021

Guangxi Medical University Affiliated Tumor Hospital, Nanning